



For immediate release – May 6, 2008

**SATISFACTORY REVENUE GROWTH
FOR 1ST QUARTER 2008:
+4.6% ON À CONSTANT BASIS**

Lure, France – May 6, 2008 – Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment.

<i>In millions of euros</i>	2008	2007	Variation
1 st quarter revenue	54.7	53.1	+3.0%
1 st quarter revenue <i>On a constant exchange rate and scope basis</i>	55.6	53.1	+4.6%

On a constant exchange rate and scope of consolidation basis, the increase was 4.6%, driven by North America (+10.7%) and certain European countries, including France and the United Kingdom.

Growth in North America was attributable in particular to the reinforcement of sales channels in the three countries, as well as to the successful launch in the United States of the drug Vetprofen, which treats pain and inflammation. Despite significant business activity in the dollar zone, the currency impact on consolidated revenue was not significant.

In Europe, growth was boosted by the success of new products in the companion animal range that were not yet sold in all European countries, and by the performance of anti-infectious medications for livestock.

"The year 2008 got off to a good start in France and in North America," noted Chairman and CEO of the Vétoquinol group Etienne Frechin. *"We are confident this year, and expect to see other new product launches. In addition, our external growth strategy should once again lead to the acquisition of a laboratory by the end of 2008."*

About Vétoquinol S.A.

Vétoquinol, established in 1933, is an independent veterinary pharmaceutical laboratory for both food producing animals and pets. This family-owned Group, dedicated to animal health, is the world's 12th largest laboratory in its field. Nearly 80% of its revenue is now generated in export markets.

Its business includes research, production and marketing of drugs and health products. Vétoquinol, positioned in the treatment field, has extensive expertise in 3 major therapeutic fields: anti-infection agents, pain and inflammatory, and cardiology-nephrology.

The Group now distributes its products in about one hundred countries (Europe, North America and Asia), working through 18 subsidiaries and a network of 110 distributor-partners. The company had more than 1,300 employees worldwide.

Upcoming events: Annual shareholders' meeting (May 19, 2008)
2008 half-year revenues (July 22, 2008)

More information: www.vetoquinol.com

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For further information, contact

VETOQUINOL

Finance Department
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor Relations
Emmanuel DOVERGNE
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr
Media Relations
Alix HÉRIARD DUBREUIL
Tel.: +33 (0)1 56 43 44 62
alix.heriard@keima.fr